Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-05
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT00027976
- Locations
- 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
🇺🇸University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States
Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00020878
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus
- Conditions
- Locations
- 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 39
- Registration Number
- NCT00045591
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Memorial Regional Cancer Center at Memorial Regional Hospital, Hollywood, Florida, United States
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT00052611
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 205
- Registration Number
- NCT00033371
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT00047281
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 21
- Registration Number
- NCT00046839
- Locations
- 🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States
🇺🇸Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States
🇺🇸Monmouth Medical Center, Long Branch, New Jersey, United States
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-02-08
- Target Recruit Count
- 73
- Registration Number
- NCT00022399
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Celecoxib in Treating Patients With Bladder Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 152
- Registration Number
- NCT00006124
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.